Is BDSI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

691 people get BDSI articles and Market Currents by email alert.

Get email alerts on BDSI »

HEADLINES:

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials

PR Newswire (May 9, 2013)
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 7, 2013)
Hedge Funds Are Buying These 3 Biotech Small Caps Trading Below Lowest Target Price
Kapitall • Wed, May 1 • 2 Comments
BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors

PR Newswire (Apr 29, 2013)
BioDelivery On Track For Mid-Year NDA Filing
Len Zehr • Wed, Apr 10 • 3 Comments
3 Companies Aiming For The $1.2B Opioid Addiction Market
Healthcare Specialist • Sun, Apr 7 • 29 Comments
BioDelivery Sciences Expands Product Pipeline with Acquisition of Patented Topical Clonidine Gel for the Treatment of Painful Diabetic Neuropathy

PR Newswire (Mar 26, 2013)
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report

PR Newswire (Mar 18, 2013)
BioDelivery Sciences to Present at the 25th Annual ROTH Conference

PR Newswire (Mar 13, 2013)
BioDelivery Sciences International's CEO Hosts R&D Day Conference (Transcript)
Fri, Mar 8
BioDelivery Sciences to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Mar 1, 2013)
BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event

PR Newswire (Feb 27, 2013)
BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference

PR Newswire (Feb 5, 2013)
BioDelivery Sciences Announces Completion of BNX Safety Study

PR Newswire (Jan 22, 2013)
The Best Stocks Of 2012
Bespoke Investment Group • Wed, Jan 2
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Sat, Dec 22, 2012 • 14 Comments
4 Biotech Names With Major Market Potential: Michael Higgins
Life Sciences Report • Thu, Dec 20, 2012 • 5 Comments
BioDelivery Sciences Announces Hiring of George Ng as General Counsel

PR Newswire (Dec 17, 2012)
What This Year's Best And Worst Stocks Say About 2013
Howard Gold • Thu, Dec 13, 2012 • 8 Comments
Russell 3000 Top Performing Stocks Year To Date
Bespoke Investment Group • Tue, Dec 11, 2012 • 1 Comment

To learn more about Seeking Alpha Pro, click here.

BioDelivery On Track For Mid-Year NDA Filing
Len Zehr • Wed, Apr 10 • 3 Comments
BioDelivery Sciences International: Making The Most Of This Small-Cap Opportunity
Adin Dobkin • Fri, Sep 7, 2012
Endo Pharma Deal Validates BioDelivery Sciences Pipeline Potential
Mike Havrilla • Tue, Jun 12, 2012
BioDelivery's Spike May Be A Short-Lived Downer
James Stocklasar Thomas Jr. • Wed, Apr 4, 2012 • 27 Comments
BioDelivery Sciences International: Strong Upside Potential
Scott Matusow • Tue, Apr 3, 2012 • 21 Comments
Legal Developments Bode Well For BioDelivery Sciences
VFC's Stock House • Thu, Mar 15, 2012
BioDelivery Sciences: A Case Of Two Steps Forward, One Step Back?
VFC's Stock House • Wed, Mar 14, 2012 • 1 Comment
BioDelivery Science: A Pipeline Rejuvenated
VFC's Stock House • Fri, Jan 13, 2012
BDSI Might Again Be Ready For Prime Time
VFC's Stock House • Sun, Jan 8, 2012
BioDelivery Sciences: Early Results Reinforce Long-Term Potential
VFC's Stock House • Wed, Sep 7, 2011 • 3 Comments
Canadian Launch Of Onsolis Has BioDelivery On The Radar
VFC's Stock House • Wed, Aug 24, 2011
BioDelivery Announces Completion of Trial; Catalyst Could Invigorate Share Price
VFC's Stock House • Wed, Jul 27, 2011 • 1 Comment
BioDelivery Sciences International: The Pieces Are Coming Together
Smith On Stocks • Mon, Mar 14, 2011 • 3 Comments
BioDelivery Sciences: An Emerging, Interesting Drug Delivery Company
Smith On Stocks • Fri, Feb 18, 2011 • 5 Comments
Time to Add BioDelivery Shares After Good Drug Trial News and Multiple Products in Pipeline
VFC's Stock House • Thu, Feb 17, 2011 • 1 Comment
BioDelivery Sciences: Signs of Life
VFC's Stock House • Fri, Sep 10, 2010 • 3 Comments
BioDelivery Sciences International: Why I Believe Patience Will Reward Investors
VFC's Stock House • Wed, May 12, 2010 • 3 Comments
Biodelivery's News Should Not Lead to Investor Panic
VFC's Stock House • Wed, Apr 21, 2010 • 5 Comments
BioDelivery Sciences Set to Take Off in 2010
VFC's Stock House • Fri, Dec 18, 2009 • 6 Comments
BioDelivery Sciences I sRestarting the Catalyst Cycle
Mike Havrilla • Thu, Oct 15, 2009 • 1 Comment

Hedge Funds Are Buying These 3 Biotech Small Caps Trading Below Lowest Target Price
Kapitall • Wed, May 1 • 2 Comments
3 Companies Aiming For The $1.2B Opioid Addiction Market
Healthcare Specialist • Sun, Apr 7 • 29 Comments
The Best Stocks Of 2012
Bespoke Investment Group • Wed, Jan 2
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Sat, Dec 22, 2012 • 14 Comments
4 Biotech Names With Major Market Potential: Michael Higgins
Life Sciences Report • Thu, Dec 20, 2012 • 5 Comments
What This Year's Best And Worst Stocks Say About 2013
Howard Gold • Thu, Dec 13, 2012 • 8 Comments
Russell 3000 Top Performing Stocks Year To Date
Bespoke Investment Group • Tue, Dec 11, 2012 • 1 Comment
Best Performing Russell 3000 Stocks YTD
Bespoke Investment Group • Thu, Nov 29, 2012
Best Performing Russell 3,000 Stocks Year-To-Date
Bespoke Investment Group • Thu, Nov 8, 2012
Weekly Stock Watch, Week Of 15 October, 2012
VFC's Stock House • Mon, Oct 15, 2012 • 2 Comments
Reckitt's Decision Opens The Door For Titan Pharma And BioDelivery Sciences
Jason Napodano • Wed, Sep 26, 2012 • 8 Comments
Best Performing Russell 3,000 Stocks And Sectors In 2012
Bespoke Investment Group • Mon, Sep 24, 2012 • 1 Comment
4 Low-Debt Healthcare Stocks Raking In Profits
ZetaKap • Fri, Sep 14, 2012
This Bio-Pharma Is Being Hyped While Insiders Are Dumping Shares
Joe Springer • Fri, Aug 24, 2012 • 79 Comments
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts This Year - Part IV
Markus Aarnio • Mon, Aug 20, 2012 • 6 Comments
5 Profit-Generating Biotech Stocks That Analysts Love
ZetaKap • Fri, Aug 17, 2012 • 1 Comment
5 Profitable Healthcare Stocks Preferred By Analysts
ZetaKap • Thu, Aug 16, 2012 • 12 Comments
7 Profitable Biotech Small Caps With Analyst Backing
ZetaKap • Tue, Jul 31, 2012 • 1 Comment
3 Pharma Companies Expected To Demonstrate Significant Growth During The Second Quarter
Matt Schilling • Mon, Jul 23, 2012 • 12 Comments
Another Weight Loss Drug Approved And Other Healthcare Sector Notes
VFC's Stock House • Wed, Jul 18, 2012 • 4 Comments

BioDelivery Sciences International's CEO Hosts R&D Day Conference (Transcript)
Fri, Mar 8

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of First Quarter 2013 Financials

PR Newswire (May 9, 2013)
BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 7, 2013)
BioDelivery Sciences Appoints Thomas W. D'Alonzo to Board of Directors

PR Newswire (Apr 29, 2013)
Top 10 U.S. cities for growing businesses

at MarketWatch.com (Apr 15, 2013)
BioDelivery Sciences Expands Product Pipeline with Acquisition of Patented Topical Clonidine Gel for the Treatment of Painful Diabetic Neuropathy

PR Newswire (Mar 26, 2013)
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report

PR Newswire (Mar 18, 2013)
BioDelivery Sciences to Present at the 25th Annual ROTH Conference

PR Newswire (Mar 13, 2013)
BioDelivery Sciences to Present at the Cowen and Company 33rd Annual Health Care Conference

PR Newswire (Mar 1, 2013)
BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event

PR Newswire (Feb 27, 2013)
BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference

PR Newswire (Feb 5, 2013)
BioDelivery Sciences Announces Completion of BNX Safety Study

PR Newswire (Jan 22, 2013)
BioDelivery Sciences Announces Hiring of George Ng as General Counsel

PR Newswire (Dec 17, 2012)
Howard Gold's No-Nonsense Investing: What 2012’s winners and losers say about 2013

at MarketWatch.com (Dec 14, 2012)
BioDelivery Sciences Announces $40 Million Registered Financing

PR Newswire (Nov 28, 2012)
BioDelivery Sciences to Present at the 24th Annual Piper Jaffray Healthcare Conference

PR Newswire (Nov 19, 2012)
BioDelivery Sciences Provides Business Update and Summary of Third Quarter Results of Operations

PR Newswire (Nov 8, 2012)
BioDelivery Sciences Reaffirms its Strengthened Position Following Reexamination of MonoSol Patents

PR Newswire (Oct 18, 2012)
BioDelivery Sciences Announces the Launch of BREAKYL (BEMA Fentanyl) in the E.U.

PR Newswire (Oct 15, 2012)
BioDelivery Sciences Announces Positive Results of Pivotal Pharmacokinetic Study Comparing BEMA Buprenorphine/Naloxone (BNX) to Suboxone

PR Newswire (Sep 13, 2012)
BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference

PR Newswire (Aug 29, 2012)

BDSI vs. ETF Alternatives

Company Description

We are a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize, either on our own or in partnerships with third parties, significant new formulations of proven therapeutics. Utilizing our drug delivery... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, April 11, 9:10 AM Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%. Comment! [On the Move]
Thursday, April 11, 8:00 AM Janney Capital initiates BioDelivery Sciences (BDSI) at Buy with a $10 price target. The stock got a compelling writeup Wednesday from SA contributor Len Zehr who says the company could capture 25% of the lucrative Suboxone market, worth ~$250M annually. Comment! [Healthcare]
Tuesday, March 26, 2:25 PM BioDelivery Sciences (BDSI +5%) gains after announcing earlier today that it's entered into a worldwide licensing agreement with privately held Arcion Therapeutics, where BDSI will develop and commercialize topical clonidine gel for the treatment of painful diabetic neuropathy and potentially other indications as well. Comment! [Healthcare, On the Move]
Tuesday, March 26, 8:21 AM BioDelivery Sciences (BDSI) announces licensing agreement with Arcion Therapeutics to develop and commercialize a topical treatment for painful diabetic neuropathy. BDSI will pay $2M upfront in unregistered shares, $2.5M upon FDA acceptance of a New Drug Application, and between $17.5M and $35M in cash upon approval. The drug has Fast Track status and the companies estimate the commercial value to be ~$300M annually. Comment! [Healthcare]
Monday, March 11, 10:46 AM BioDelivery Sciences International (BDSI +3%) gets a boost from a Piper Jaffray upgrade to Overweight. Piper calls BDSI a value-added offering for pain and expects Phase III bioequivalence data for Bunavail to show a possible superiority to its other generic opioid dependence treatment Suboxone. Bunavail's NDA filing is planned for July and Phase III readout is expected by year-end or early 2014. Comment! [Healthcare, On the Move]
Tuesday, April 17, 2012, 8:28 AM BioDelivery Sciences (BDSI) lands patent approval from the USPTO that will extend its protection on BioErodible MucoAdhesive (BEMA) products, BEMA Buprenorphine and BEMA Buprenorphine/Naloxone. As a result of the action, the firm will land a $15M milestone payment from Endo Pharmaceuticals. 1 Comment [Healthcare]
Monday, March 12, 2012, 3:38 PM BioDelivery Sciences International (BDSI -6.8%) falls after saying it will delay the relaunch of its Onsolis painkiller to modify the product amid questions from the FDA related to the product's appearance. Comment! [Healthcare, On the Move]
Tuesday, February 28, 2012, 7:23 AM BioDelivery Sciences (BDSI) announces that it reached an agreement with the FDA concerning the development program for its BEMA Buprenorphine/Naloxone drug. The firm says that it anticipates following a plan which would set it up to file for a NDA for the drug in H1 of 2013. Comment! [Healthcare]
Wednesday, February 22, 2012, 10:53 AM The USPTO rejects all claims made against BioDelivery Sciences (BDSI +1.1%) by MonoSol over patents relating to a thin film manufacturing process the company uses. Comment! [Tech]
Friday, January 6, 2012, 7:24 AM Shares of BioDelivery Sciences (BDSI) shoot up 33% premarket after the firm announces a worldwide license and development agreement with Endo Pharmaceuticals (ENDP) for the rights to commercialize chronic pain treatment BEMA Buprenorphine. Comment! [On the Move, Healthcare]
Thursday, December 29, 2011, 3:04 PM Microcap BioDelivery Sciences (BDSI +21.1%) soars after the firm lands FDA approval for a risk strategy covering all transmucosal fentanyl products for pain management. Comment! [On the Move, Healthcare]
Thursday, September 29, 2011, 8:30 AM BioDelivery Sciences (BDSI) drops 49% premarket after announcing preliminary results for a Phase 3 study for its BEMA Buprenorphine pain relief drug failed to report a difference in overall pain intensity between those taking the drug, and those taking a placebo. Comment! [Healthcare, On the Move]
Wednesday, September 28, 2011, 6:34 PM BioDelivery Sciences International (BDSI) gets hammered post-trading after it says preliminary findings of its Phase 3 clinical study of BEMA Buprenorphine for the treatment of moderate to severe chronic pain were unsuccessful. Shares -42% AH. Comment!
Wednesday, July 22, 2009, 9:00 AM Premarket gainers: ONXX +32%. ATHR +11%. AAI +9%. SBUX +9%. BDSI +8%. CKSW +6%. AKRX +4%. AAPL +4%. STX +4%. HGSI +4%.
Losers: AMD -14%. PPDI -13%. AAN -12%. CIT -8%. RSH -7%. KEY -6%. WFC -6%. HEB -6%. SAY -6%. MS -5%. ERX -4%. SLM -4%. YHOO -4%. CVBF -4%. RCL -4%. GILD -4%. BK -4%. CHU -4%. SQNM -4%. Comment!
Monday, June 15, 2009, 9:00 AM Premarket gainers: BDSI +24%. HBAN +13%. CTIC +9%. IMMU +7%. HEB +4%. TQNT +4%.
Losers: GNBT -11%. IRE -9%. LNC -8%. AAV -7%. AIB -7%. LEA -7%. CENX -6%. RTP -6%. STM -6%. TGB -6%. SAY -5%. ESLR -5%. CIT -5%. MT -4%. JASO -4%. Comment!
Thursday, January 15, 2009, 9:04 AM Cypress Bioscience (CYPB +39%) and Forest Labs (FRX +7.5%) get FDA approval for Savella in fibromyalgia treatment. Other stocks that could see an FDA bump: AMAG Pharma (AMAG), BioDelivery Sciences (BDSI), Momenta Pharma (MNTA). (more) Comment!

Kapitall
Hedge Funds Are Buying These 3 Biotech Small Caps Trading Below Lowest Target Price $BDSI $NVAX $QCOR http://seekingalpha.com/a/trpf
May 1, 6:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Low-Debt Healthcare Stocks Raking In Profits http://bit.ly/RWUMlj $BDSI $MNTA $POZN $TARO @ZetaKap
9/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Retail Investor: $TARO shareholders pls read this before casting your vote http://bit.ly/ST8vWQ
10/6/12
• !Report Abuse
Add a reply...

140 characters

ZetaKap
5 Profit-Generating Biotech Stocks That Analysts Love http://bit.ly/PpNyEQ $BDSI $BSTC $CBPO $IMMU $QCOR @ZetaKap
8/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Profitable Healthcare Stocks Preferred By Analysts http://bit.ly/R3SeBs $BDSI $DUSA $HLF $IMMU $QCOR @ZetaKap
8/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Profitable Biotech Small Caps With Analyst Backing http://bit.ly/OH8ZAK $BDSI $OMPI $SIGA $SPPI $PGNX $MNTA $EXEL @ZetaKap
7/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Mike Havrilla
$BDSI $CPRX $MDVN $ONXX BioRunUp.com FDA and clinical trial catalyst updates at http://bit.ly/fu9kA5
6/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jim Van Meerten
BDSI - 96% Barchart technicanl buy signal - 16 new highs and up 63.09% in the lst month - Relative Strength Index 85.48%
4/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
I expect my pick $PSDV to meet or exceed my short term target like with $BDSI. Lots of catalysts upcoming soon there.
4/19/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Michael Bryant
BioDelivery Sciences International (BDSI) could be breaking out. http://yhoo.it/IkEnkn;c=
4/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Scott Matusow
$BDSI should be on the move today. Another lucky call from me, right? Writing a strong piece on another comp I hope to have out soon.
4/17/12
Reply (16)

• !Report Abuse
View all 16 replies
Scott Matusow: $2.50 not overbought IMO, check prior volume and chart pattern. shares being held tight there.
4/17/12
• !Report Abuse
wiesemc: Good point about vol.
4/17/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

ZetaKap
4 Low-Debt Healthcare Stocks Raking In Profits http://bit.ly/RWUMlj $BDSI $MNTA $POZN $TARO @ZetaKap
9/14/12
Reply (1)

• !Report Abuse
View all 1 replies
Retail Investor: $TARO shareholders pls read this before casting your vote http://bit.ly/ST8vWQ
10/6/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$BDSI should be on the move today. Another lucky call from me, right? Writing a strong piece on another comp I hope to have out soon.
4/17/12
Reply (16)

• !Report Abuse
View all 16 replies
Scott Matusow: $2.50 not overbought IMO, check prior volume and chart pattern. shares being held tight there.
4/17/12
• !Report Abuse
wiesemc: Good point about vol.
4/17/12
• !Report Abuse
Add a reply...

140 characters

Scott Matusow
$BDSI looking pretty good, should run to near 3 if over all market helps. maintain 3.05 short term target
4/3/12
Reply (1)

• !Report Abuse
View all 1 replies
flyisu2002: Yes sir $bdsi should be good day tomorrow and the next especially if market is up.
4/4/12
• !Report Abuse
Add a reply...

140 characters

BDSI BioDelivery Sciences International, Inc.

BDSI

BioDelivery Sciences International, Inc.